Khan A, Murphy AB. Updates on therapies for chronic prostatitis/chronic pelvic pain syndrome. World J Pharmacol 2015; 4(1): 1-16 [DOI: 10.5497/wjp.v4.i1.1]
Corresponding Author of This Article
Asfandyar Khan, MD, Department of Urology, Northwestern University Feinberg School of Medicine, 303 E. Chicago Ave., Tarry 16-729, Chicago, IL 60611, United States. a-khan@northwestern.edu
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Pharmacol. Mar 9, 2015; 4(1): 1-16 Published online Mar 9, 2015. doi: 10.5497/wjp.v4.i1.1
Updates on therapies for chronic prostatitis/chronic pelvic pain syndrome
Asfandyar Khan, Adam B Murphy
Asfandyar Khan, Adam B Murphy, Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States
Author contributions: Khan A and Murphy AB contributed equally to this work.
Conflict-of-interest: The authors declare no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Asfandyar Khan, MD, Department of Urology, Northwestern University Feinberg School of Medicine, 303 E. Chicago Ave., Tarry 16-729, Chicago, IL 60611, United States. a-khan@northwestern.edu
Telephone: +1-312-9082002
Received: July 10, 2014 Peer-review started: July 10, 2014 First decision: September 16, 2014 Revised: October 22, 2014 Accepted: December 16, 2014 Article in press: December 17, 2014 Published online: March 9, 2015 Processing time: 246 Days and 16.3 Hours
Core Tip
Core tip: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is difficult-to-treat because of the multitude of potential etiologies that are not easily observed and delayed diagnosis. Pharmacological monotherapy with antibiotics, alpha-blockers and anti-inflammatories provide significant symptomatic improvement in a limited number of patients. Multidrug therapies are recommended for monotherapy refractory patients. Complementary and interventional therapies such as acupuncture, myofascial trigger point release and pelvic floor biofeedback can provide additional symptomatic relief. Current recommendations involve a treatment algorithm based on UPOINT phenotypic presentation for CP/CPPS patients. Keeping in mind the high prevalence of CP/CPPS, development of novel therapies and an effective vaccine for prevention of CP/CPPS is crucial.
